drugset / Trial / NCT03532880

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

NCT03532880

Phase 1 Completed 26 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.

Timeline

Start
2018-07-12
Primary completion
2025-02-04
Completion
2025-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 50 mg Oral
Subject Olaparib Small molecule 100 mg Oral
Subject Olaparib Small molecule 150 mg Oral
Subject Olaparib Small molecule 200 mg Oral
Subject Olaparib Small molecule 250 mg Oral
Subject Olaparib Small molecule 300 mg Oral